Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01346969 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT01346969 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 68 participants.
The verdict
NCT01346969, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The study will investigate the efficacy of various doses and regimens of EXC 001 in reducing skin scarring in subjects undergoing revision of scars from prior surgery. The study will also evaluate the safety and tolerability of EXC 001 and placebo.
Interventions
- DRUG EXC 001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-06-01 |
| Est. Completion | 2012-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01346969
The ClinicalTrials.gov registry entry for NCT01346969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EXC 001 is the first listed.
NCT01346969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01346969 about?
NCT01346969 is a clinical study titled "Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery". The study will investigate the efficacy of various doses and regimens of EXC 001 in reducing skin scarring in subjects undergoing revision of scars from prior surgery. The study will also evaluate the safety and tolerability of EXC 001 and placebo.
What is the current status of trial NCT01346969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2011-06-01. Estimated completion is 2012-04-16.
What interventions are being tested in trial NCT01346969?
The interventions under investigation include: EXC 001 (DRUG).
Who is sponsoring clinical trial NCT01346969?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.